Month: August 2025

WAYNE, Pa., Aug. 27, 2025 (GLOBE NEWSWIRE) — Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the Company will participate in two upcoming healthcare conferences in September.On Wednesday September 3, 2025, at 1:00 PM EDT, Aclaris’ Chief Executive Officer Dr. Neal Walker and other members of Aclaris’ senior leadership team will participate in a fireside chat during the Cantor Global Healthcare Conference in New York, NY.On Tuesday September 9, 2025, at 9:00 AM EDT, Dr. Walker will provide a corporate presentation during the H.C. Wainwright 27th Annual Global Investment Conference in New York, NY.Live and archived webcasts of both events will be accessible on the Events page of https://www.aclaristx.com/....

ATHENS, Greece, Aug. 27, 2025 (GLOBE NEWSWIRE) — C3is Inc. (Nasdaq: CISS) (the “Company”), a ship-owning company providing seaborne transportation services, announced today that it will release its second quarter financial results for the period ended June 30, 2025 before the market opens in New York on September 2, 2025. On September 2, 2025 at 10:00 am ET, the company’s management will host a conference call to present the results and the company’s operations and outlook. Slides and audio webcast: There will also be a live and then archived webcast of the conference call, through the C3is Inc. website (www.c3is.pro). Participants to the live webcast should register on the website approximately 10 minutes prior to the start of the webcast. Please note that this will be a listen-only mode presentation. ABOUT C3is Inc. C3is Inc....

New Peer-Reviewed Publication Highlights Landmark Meeting Co-Sponsored by LIXTE DENVER, Aug. 27, 2025 (GLOBE NEWSWIRE) — 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and corporate information, highlights the publication of a new manuscript in Trends in Cancer (July 2025, Vol. 11, No. 7, https://doi.org/10.1016/j.trecan.2025.04.009) describing the first international conference on activation of oncogenic signaling as a cancer treatment strategy. The landmark meeting was co-sponsored by LIXTE Biotechnology Holdings, Inc. (NASDAQ: LIXT) and co-organized by Professor Rene Bernards, and board member of LIXTE. At the conference, compelling new data was presented showing that LIXTE’s lead compound LB-100 can mediate activation of oncogenic signaling, a process that proves toxic...

TORONTO, Aug. 27, 2025 (GLOBE NEWSWIRE) — New Horizon Aircraft (NASDAQ: HOVR), doing business as Horizon Aircraft (“Horizon” or the “Company”), an advanced aerospace engineering company and developer of one of the world’s first hybrid electric Vertical Take-Off and Landing (VTOL) aircraft, today announced that its management team will participate in the following conferences in September: Event: Gabelli Aerospace & Defense SymposiumDate: September 4, 2025Location: New York City – The Harvard ClubLink: https://gabelli.com/event/31st-annual-aerospace-defense-symposium/Management will participate in a fireside chat at 7:45am ET and 1×1 investor meetings. Investors should register at the above link for access to the live fireside chat webcast. Event: Deutsche Bank Aviation Forum: Airlines, Lessors, ManufacturersDate: September...

Initial collaboration led to Tyvaso DPI®, the first FDA-approved dry powder inhalation treatment for pulmonary hypertension DANBURY, Conn. and BOSTON, Aug. 27, 2025 (GLOBE NEWSWIRE) —  MannKind Corporation (Nasdaq: MNKD) today announced that United Therapeutics Corporation (Nasdaq: UTHR) has exercised its option—granted under the companies’ 2018 license and collaboration agreement—to develop a second dry powder inhalation therapy. The original agreement, which led to U.S. FDA approval of Tyvaso DPI in May 2022, included an option for United Therapeutics to expand the license to include additional active ingredients. Under the terms of the expanded agreement, MannKind will formulate a second investigational molecule using its proprietary Technosphere® platform, and United Therapeutics will conduct preclinical and clinical development. “Building...

Presenting Data from CLOVER-2 Phase 1 Clinical Study Evaluating Iopofosine I 131 in Relapsed/Refractory Pediatric High-Grade Glioma (r/r pHGG) Patients FLORHAM PARK, N.J., Aug. 27, 2025 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the acceptance of an abstract for oral presentation followed by a 55-minute panel discussion with other experts in this area at the American Association for Cancer Research (AACR) Special Conference on Pediatric Cancer taking place September 25-28 in Boston, Massachusetts. The oral presentation will highlight interim data from the Phase 1b dose and regimen optimization study of iopofosine I 131 in inoperable relapsed or refractory pediatric high-grade...

US Food and Drug Administration (FDA) has granted Fast Track designation for NRX-100 in the treatment of suicidal ideation in patients with depression, including bipolar depression. NRx Pharmaceuticals is making NRX-100 available on an expanded access basis upon physician request for patients with serious or life-threatening suicidal depression despite treatment with currently available therapy. Approximately 13 million adults seriously consider suicide each year, according to the CDC. An American dies from suicide every 11 minutes. Physicians may apply for expanded access on behalf of patients who meet expanded access criteria by writing to expandedaccess@nrxpharma.com. Further information may be viewed at https://www.nrxpharma.com/expandedaccess/nrx-100.WILMINGTON, Del., Aug. 27, 2025 (GLOBE NEWSWIRE) — NRx Pharmaceuticals,...

GAITHERSBURG, Md., Aug. 27, 2025 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s senior management team will participate in the following investor conferences:Wells Fargo 20th Annual Healthcare ConferenceSeptember 4, 20253:00 pm ETWebcast link hereOne-on-one meetingsHCW 27th Annual Global Investment ConferenceSeptember 9, 20251:30 PM ETWebcast link hereOne-on-one meetingsPlease contact your conference representative to request one-on-one meetings. Participants can view the presentations and replays by visiting the Investors page of Emergent’s website. About Emergent BioSolutionsAt Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions...